The standard of care treatment strategy for patients with relapsed or refractory large B-cell
lymphoma (LBCL) has been high-dose chemotherapy followed by autologous stem cell …

B-cell lymphoma is a group of hematological malignancies with high clinical and biological
heterogeneity. The pathogenesis of B-cell lymphoma involves a complex interaction …

Background The prognosis for patients with relapsed or refractory diffuse large B-cell
lymphoma (DLBCL) is poor. Glofitamab is a bispecific antibody that recruits T cells to tumor …

Background In an analysis of the primary outcome of this phase 3 trial, patients with early
relapsed or refractory large B-cell lymphoma who received axicabtagene ciloleucel (axi-cel) …

PURPOSE Epcoritamab is a subcutaneously administered CD3xCD20 T-cell–engaging,
bispecific antibody that activates T cells, directing them to kill malignant CD20+ B cells …

Background The prognosis of patients with early relapsed or refractory large B-cell
lymphoma after the receipt of first-line chemoimmunotherapy is poor. Methods In this …

Background Diffuse large B-cell lymphoma (DLBCL) is typically treated with rituximab,
cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). However, only 60 …

Background Patient outcomes are poor for aggressive B-cell non-Hodgkin's lymphomas not
responding to or progressing within 12 months after first-line therapy. Tisagenlecleucel is an …

High-risk large B-cell lymphoma (LBCL) has poor outcomes with standard first-line
chemoimmunotherapy. In the phase 2, multicenter, single-arm ZUMA-12 study …

Axicabtagene ciloleucel (axi-cel) demonstrated superior efficacy compared to standard of
care as second-line therapy in patients with high-risk relapsed/refractory (R/R) large B cell …